This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Topic Collections  • Psychiatry  • Adverse Effects  • Alert me on articles by topic

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: Dr Rosenheck and colleagues¹ concluded that the atypical antipsychotic drug olanzapine was unlikely to be more cost-effective than haloperidol.² Furthermore, the literature suggests that there is no significant difference between these atypical drugs in terms of either efficacy or effectiveness.³ Atypical antipsychotic drugs differ among themselves and from conventional antipsychotics in terms of their tendency to produce endocrinological adverse effects.^3-4 The study by Rosenheck et al found that a significant portion of the added costs of olanzapine was related to weight gain, an endocrine adverse effect. Thus, the authors' results suggest that future cost-effectiveness analyses of atypical antipsychotics should take endocrinological adverse effects into account.

We doubt that it is possible to measure quality of life without considering adverse effects, some of which may also be associated with significant monetary costs. Given that atypical antipsychotic drugs have similar efficacy and effectiveness, we suspect that future decisions about . . . [Full Text of this Article]

Mo Amin, BSc, MSc, PhD
moa@ccohta.ca

Vijay S. Shukla, BPharm, MSc, PhD
Canadian Coordinating Office for Health Technology Assessment
Ottawa, Ontario

RELATED ARTICLES

Olanzapine vs Haloperidol for Treatment of Schizophrenia
Jan Volavka and Leslie Citrome
JAMA. 2004;291(9):1064.
EXTRACT | FULL TEXT  

Olanzapine vs Haloperidol for Treatment of Schizophrenia
William M. Glazer
JAMA. 2004;291(9):1064-1065.
EXTRACT | FULL TEXT  

Olanzapine vs Haloperidol for Treatment of Schizophrenia
Michal Kunz
JAMA. 2004;291(9):1065.
EXTRACT | FULL TEXT  

Olanzapine vs Haloperidol for Treatment of Schizophrenia
Lieuwe de Haan and Nico van Beveren
JAMA. 2004;291(9):1065.
EXTRACT | FULL TEXT  

Olanzapine vs Haloperidol for Treatment of Schizophrenia—Reply
Robert Rosenheck, Deborah Perlick, Stephen Bingham, and Joseph Collins
JAMA. 2004;291(9):1065-1066.
EXTRACT | FULL TEXT  

Effectiveness and Cost of Olanzapine and Haloperidol in the Treatment of Schizophrenia: A Randomized Controlled Trial
Robert Rosenheck, Deborah Perlick, Stephen Bingham, Wen Liu-Mares, Joseph Collins, Stuart Warren, Douglas Leslie, Edward Allan, E. Cabrina Campbell, Stanley Caroff, June Corwin, Lori Davis, Richard Douyon, Lawrence Dunn, Denise Evans, Ede Frecska, John Grabowski, David Graeber, Lawrence Herz, Kong Kwon, William Lawson, Felicitas Mena, Javaid Sheikh, David Smelson, and Valerie Smith-Gamble
JAMA. 2003;290(20):2693-2702.
ABSTRACT | FULL TEXT